Antibody kinetics among 8-10 years old respondents to hepatitis B vaccination in a low endemic country and the effect of a booster dose given 5 or 10 years later

[Guest guest]

Vaccine. 2009 Aug 14. [Epub ahead of print]

Antibody kinetics among 8-10 years old respondents to hepatitis B vaccination in

a low endemic country and the effect of a booster dose given 5 or 10 years

later.

Gilca V, De Serres G, Boulianne N, De Wals P, D, Trudeau G, Massé R,

Duval B.

Institut national de santé publique du Québec, Laval University, Quebec, Canada.

Few data are available concerning the persistence of anti-HBs and the effect of

booster doses given several years post-vaccination against hepatitis B during

preadolescence. The objective of this open-labelled clinical trial was to

evaluate the persistence of antibodies after vaccination with three paediatric

doses of Engerix-B at the age of 8-10 years and the effect of a booster dose

given 5 (Group Y5) or 10 (Group Y10) years later. Anti-HBs were measured before

and one month post-primary vaccination, then 5 and 10 years later, before the

booster dose, as well as one month and 1 year post-booster. The anamnestic

response was defined as a>/=fourfold increase of anti-HBs post-booster

(>/=10IU/L) when compared to pre-booster. Ten years post-primary vaccination,

559 of the 652 initially randomized subjects (86%) were eligible for analysis.

Group Y5, 5 years post-booster results: 99% of subjects had detectable levels of

antibodies and 96% a titer>/=10IU/L. The anti-HBs GMTs decreased from

114,489IU/L one month post-booster to 3354IU/L 5 years later. Group Y10 results:

10 years post-primary vaccination 96% of subjects had a detectable level of

anti-HBs and 85% were above the threshold of 10IU/L. The GMTs one month

post-booster were 31,030IU/L. The challenge with a booster demonstrated an

anamnestic response in 99% of subjects in group Y5 and 100% of subjects in group

Y10. All subjects were anti-HBc negative. The booster doses were well tolerated.

The excellent anamnestic response observed after the booster dose demonstrates

the persistence of immunity in virtually all young adults vaccinated at the age

of 8-10 with three paediatric doses of Engerix-B.

PMID: 19683086 [PubMed - as supplied by publisher]

[Guest guest]

Vaccine. 2009 Aug 14. [Epub ahead of print]

Antibody kinetics among 8-10 years old respondents to hepatitis B vaccination in

a low endemic country and the effect of a booster dose given 5 or 10 years

later.

Gilca V, De Serres G, Boulianne N, De Wals P, D, Trudeau G, Massé R,

Duval B.

Institut national de santé publique du Québec, Laval University, Quebec, Canada.

Few data are available concerning the persistence of anti-HBs and the effect of

booster doses given several years post-vaccination against hepatitis B during

preadolescence. The objective of this open-labelled clinical trial was to

evaluate the persistence of antibodies after vaccination with three paediatric

doses of Engerix-B at the age of 8-10 years and the effect of a booster dose

given 5 (Group Y5) or 10 (Group Y10) years later. Anti-HBs were measured before

and one month post-primary vaccination, then 5 and 10 years later, before the

booster dose, as well as one month and 1 year post-booster. The anamnestic

response was defined as a>/=fourfold increase of anti-HBs post-booster

(>/=10IU/L) when compared to pre-booster. Ten years post-primary vaccination,

559 of the 652 initially randomized subjects (86%) were eligible for analysis.

Group Y5, 5 years post-booster results: 99% of subjects had detectable levels of

antibodies and 96% a titer>/=10IU/L. The anti-HBs GMTs decreased from

114,489IU/L one month post-booster to 3354IU/L 5 years later. Group Y10 results:

10 years post-primary vaccination 96% of subjects had a detectable level of

anti-HBs and 85% were above the threshold of 10IU/L. The GMTs one month

post-booster were 31,030IU/L. The challenge with a booster demonstrated an

anamnestic response in 99% of subjects in group Y5 and 100% of subjects in group

Y10. All subjects were anti-HBc negative. The booster doses were well tolerated.

The excellent anamnestic response observed after the booster dose demonstrates

the persistence of immunity in virtually all young adults vaccinated at the age

of 8-10 with three paediatric doses of Engerix-B.

PMID: 19683086 [PubMed - as supplied by publisher]